Provided by Tiger Trade Technology Pte. Ltd.

BridgeBio Pharma, Inc.

72.38
-0.0600-0.08%
Post-market: 72.380.00000.00%19:30 EDT
Volume:1.85M
Turnover:134.41M
Market Cap:14.17B
PE:-20.28
High:73.67
Open:72.55
Low:72.17
Close:72.44
52wk High:93.42
52wk Low:48.78
Shares:195.81M
Float Shares:167.00M
Volume Ratio:0.86
T/O Rate:1.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5686
EPS(LYR):-3.7850
ROE:-1789.67%
ROA:-26.00%
PB:-5.63
PE(LYR):-19.12

Loading ...

Movement Alert|BridgeBio Pharma Rises 5.31% in Pre-Market Trading, $1 Billion Preferred Equity Financing Fuels Rare Disease Pipeline Commercialization

Market Focus
·
Jul 09

Astrazeneca's Wainua Fails Key Heart Disease Trial, Shares Tumble

Reuters
·
Jul 09

Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD), Teva Pharmaceutical (TEVA) and BridgeBio Pharma (BBIO)

TIPRANKS
·
Jul 08

BridgeBio Pharma (BBIO) Gets a Buy from Jefferies

TIPRANKS
·
Jul 06

Bridgebio Raises up to $1 Billion in Convertible Preferred Equity Private Placement Led by Sixth Street

Reuters
·
Jul 03

Bridgebio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches

THOMSON REUTERS
·
Jul 01

Bridgebio Pharma - Sixth Street Funded $800 Mln; Healthcare Royalty Funded $133.9 Mln at Close

THOMSON REUTERS
·
Jul 01

Market Chatter: KKR, Sixth Street to Invest $1 Billion in BridgeBio Preferred Equity

MT Newswires Live
·
Jul 01

Sixth Street, KKR Provide Bridgebio $1 Billion Preferred Equity- Bloomberg News

Reuters
·
Jul 01

Why BridgeBio Pharma (BBIO) Is Up 8.5% After NEJM-Published Infigratinib Phase 3 Achondroplasia Data

Simply Wall St.
·
Jul 01

Sector Update: Healthcare

MT Newswires Live
·
Jun 29

BridgeBio Pharma Meets Primary Endpoint For Achondroplasia Drug in Phase 3 Trial

MT Newswires Live
·
Jun 29

BridgeBio announces PROPEL 3 trial met primary endpoint

TIPRANKS
·
Jun 29

Bridgebio Says Phase 3 Propel 3 Trial Shows Oral Infigratinib Boosts Growth in Children with Achondroplasia

Reuters
·
Jun 29

Bridgebio Announces Publication in the New England Journal of Medicine of Phase 3 Propel 3 Trial of Oral Infigratinib in Children Living with Achondroplasia

THOMSON REUTERS
·
Jun 29

Bridgebio Shareholders Approved 2 Million-share Increase Under 2021 Equity Plan at Annual Meeting

Reuters
·
Jun 26

Bridgebio Director Hannah Valantine Disposes of Common Shares Worth $341,571.72

Reuters
·
Jun 25

BRIEF-Bridgebio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Jun 24

BridgeBio Pharma grants 66,810 restricted stock units to 30 new employees under inducement plan

Reuters
·
Jun 24

BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jun 24